



CHD4 is essential for transcriptional repression and lineage progression in B lymphopoiesis

Tessa Arends^{a,1}, Carissa Dege^{b,1}, Alexandra Bortnick^c, Thomas Danhorn^d, Jennifer R. Knapp^d, Haiqun Jia^e, Laura Harmacek^d, Courtney J. Fleenor^f, Desiree Straign^f, Kendra Walton^d, Sonia M. Leach^{d,f}, Ann J. Feeney^e, Cornelis Murre^c, Brian P. O'Connor^{b,d,f,1}, and James R. Hagman^{a,b,f,1,2}

^aProgram in Molecular Biology, University of Colorado Denver, Aurora, CO 80045; ^bDepartment of Immunology and Microbiology, University of Colorado Denver, Aurora, CO 80045; ^cSection of Molecular Biology, University of California, San Diego, La Jolla, CA 92093; ^dCenter for Genes, Environment, and Health, National Jewish Health, Denver, CO 80206; ^eDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037; and ^fDepartment of Biomedical Research, National Jewish Health, Denver, CO 80206

Edited by Max D. Cooper, Emory University, Atlanta, GA, and approved April 17, 2019 (received for review December 28, 2018)

Cell lineage specification is a tightly regulated process that is dependent on appropriate expression of lineage and developmental stage-specific transcriptional programs. Here, we show that Chromodomain Helicase DNA-binding protein 4 (CHD4), a major ATPase/helicase subunit of Nucleosome Remodeling and Deacetylase Complexes (NuRD) in lymphocytes, is essential for specification of the early B cell lineage transcriptional program. In the absence of CHD4 in B cell progenitors *in vivo*, development of these cells is arrested at an early pro-B-like stage that is unresponsive to IL-7 receptor signaling and unable to efficiently complete V(D)J rearrangements at *Igh* loci. Our studies confirm that chromatin accessibility and transcription of thousands of gene loci are controlled dynamically by CHD4 during early B cell development. Strikingly, CHD4-deficient pro-B cells express transcripts of many non-B cell lineage genes, including genes that are characteristic of other hematopoietic lineages, neuronal cells, and the CNS, lung, pancreas, and other cell types. We conclude that CHD4 inhibits inappropriate transcription in pro-B cells. Together, our data demonstrate the importance of CHD4 in establishing and maintaining an appropriate transcriptome in early B lymphopoiesis via chromatin accessibility.

B lymphopoiesis | B lymphocyte development | transcriptional programming | transcriptional repression | chromatin remodeling complexes

A complex network of intrinsic and extrinsic factors regulates the differentiation of hematopoietic stem cells (HSCs) into diverse blood cell lineages, including B lymphocytes. B cell lineage specification is a function of cell- and stage-specific transcription, which is tightly controlled during B lymphopoiesis in the bone marrow. Master transcriptional regulators of B cell specification and commitment have been studied in depth. These factors, including Early B cell factor 1 (EBF1), TCF3 (E2A proteins E12 and E47), Ikaros (IKZF1), FoxO1, Pax5, and IRF4, are sequence-specific DNA binding proteins that bind regulatory modules in key genes to activate the B cell transcriptional program and repress non-B cell-specific genes (1–3). These factors recruit epigenetic regulators that control chromatin accessibility and transcriptional priming at specific gene loci to initiate B cell programming (4–7). In this regard, nucleosome mobilization by chromatin remodeling complexes (CRCs) is emerging as critical for the dynamic regulation and interconvertibility of active, poised, or silent gene loci in cell type specification and subsequent differentiation.

Nucleosome Remodeling and Deacetylase (NuRD; also known as Mi-2) was first characterized as a multiprotein complex that combines both ATP-dependent nucleosome mobilization and histone deacetylase activities (8–10). NuRD has been implicated in the regulation of transcriptional programs in both B and T lymphocytes (11). Of central importance for its function, NuRD components Chromodomain Helicase DNA-binding 4 (CHD4; also known as Mi-2 β), CHD3 (Mi-2 α ; encoded by a separate gene), and CHD5 (restricted to the central nervous system), are members of the SNF2/RAD54 helicase family that unite ATP-

dependent nucleosome remodeling functions with “reader” domains that bind histone tails. Each of these proteins comprises a core ATPase/helicase domain flanked by two Plant Homeodomain motifs (PHD fingers) that recognize modifications of histone tails, tandem chromodomains, and carboxyl-terminal domains necessary for transcriptional repression (12–16). Studies also identified components of NuRD complexes that assemble in a combinatorial fashion. CHD3, CHD4, and CHD5 each associate with five other core subunits that assemble as preformed higher order complexes (17–19). In this manner, CHD proteins combine their activities with HDAC1/HDAC2, MBD2/MBD3, WD40 repeat proteins RBBP4/RBBP7; metastasis-associated proteins MTA-1, MTA-2, or MTA-3; and the GATAD2A/B zinc finger proteins. Together, these complexes focus an extensive array of activities for chromatin remodeling and epigenetic regulation.

Importantly, CHD4-NuRD complexes do not recognize specific DNA sequences. Instead, they are recruited to sites by interactions with sequence-specific DNA binding proteins (e.g., BCL6 and Ikaros) (20–26). Subsequently, local chromatin structure is modified by mobilization of nucleosomes, histone deacetylation, and

Significance

The ontogeny of B cells in the bone marrow is regulated by a complex network of proteins and signaling pathways. Regulation of gene expression through transcriptional activation and repression is necessary for establishing and maintaining appropriate transcriptomes in cellular development. Here we show that CHD4, a protein that combines epigenetic reader and nucleosome mobilizing functions, is indispensable for early B cell lineage specification and progression. CHD4 is required for IL-7 receptor signaling and efficient V(D)J recombination. Furthermore, CHD4 is essential for repression of non-B lineage gene transcription during B lymphopoiesis. Together, our findings define the importance of a key epigenetic regulator in B cell development and gene expression.

Author contributions: T.A., C.D., A.J.F., C.M., B.P.O., and J.R.H. designed research; T.A., C.D., A.B., H.J., L.H., C.J.F., D.S., K.W., and J.R.H. performed research; C.M. contributed new reagents/analytic tools; T.A., C.D., T.D., J.R.K., H.J., S.M.L., A.J.F., C.M., B.P.O., and J.R.H. analyzed data; and T.A., C.D., B.P.O., and J.R.H. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

Data deposition: The RNA-seq and ATAC-seq data have been deposited in the NCBI Gene Expression Omnibus (GEO; www.ncbi.nlm.nih.gov/geo/) under accession number GSE123504.

¹T.A., C.D., B.P.O., and J.R.H. contributed equally to this work.

²To whom correspondence should be addressed. Email: hagmanj@njhealth.org.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1821301116/-DCSupplemental.

Published online May 13, 2019.

subsequent “decommissioning” of promoters (25, 27, 28). Thus, CHD4-NuRD has been revealed as an integral driver of appropriate transcription during cell type specification. Complementing its roles in CHD4-NuRD complexes, CHD4’s ability to be recruited independently of NuRD enables additional functions in DNA damage repair and cell cycle progression (29–33), signal transduction (34), and overall genome maintenance (35).

We previously demonstrated the importance of CHD4-NuRD complexes in regulating chromatin accessibility in B cell-specific transcription (14, 16, 36). To further understand how CHD4 contributes to specification of the B cell lineage, we assessed functions of CHD4 in vivo. In mice lacking CHD4 specifically in B cell progenitors, development is arrested at an early pro-B-like stage. CHD4-deficient pro-B cells do not proliferate in response to IL-7 and exhibit decreased phosphorylated Signal Transducer and Activator of Transcription 5A (STAT5A). The cells also feature greatly reduced frequencies of distal V_H gene segment usage in V(D)J recombination, with undetectable expression of cytoplasmic μ -chains. Notably, CHD4-deficient pro-B cells expressed hundreds of non-B cell lineage genes out of context. Expression of these genes was due, in part, to greatly increased chromatin accessibility at intronic and intergenic elements. Together, our observations confirm that CHD4 is essential for B cell specification through its roles in cell homeostasis, V(D)J recombination, and repression of inappropriate transcription in early B lymphopoiesis.

Results

B Cell Development Is Arrested at an Early Pro-B Stage in the Absence of CHD4. To assess roles of CHD4 in B cell development in vivo, we bred *Chd4*-floxed (*Chd4^{fl/fl}*) mice (37) with transgenic mice that express Cre recombinase under the direction of the early B cell-specific *CD79a* gene (*CD79a-Cre^{Tg/+}*) (38, 39). In resulting *Chd4* conditional knock-out (*Chd4^{cKO/cKO}*) mice, Cre expression and *Chd4* deletion occur at the prepro-B to pro-B cell transition during B cell development in the bone marrow (SI Appendix, Fig. S1 A and B). Total cellularity of bone marrow and spleens was decreased in *Chd4^{cKO/cKO}* mice compared with littermate controls (Fig. 1 A and B). *Chd4^{cKO/cKO}* mice exhibited a 90% reduction in the frequency and number of B cells ($B220^+CD19^+$) in the bone marrow (Fig. 1 C and D). Notably, a $B220^+CD19^+$ population was only observed in *Chd4^{cKO/cKO}* mice (Fig. 1C).

To characterize effects of CHD4 depletion on B cell differentiation in the bone marrow, we analyzed the Hardy phenotypic fractions of bone marrow B cells using flow cytometry (Fig. 2) (40, 41). Characterization of phenotypic fractions used were prepro-B cells (fraction A; $B220^+CD43^+BP1^-CD24^{low/-}$), a distinct population (not included in B cell fractions characterized by Hardy and colleagues) encompassing early pro-B cells (fraction A/B; $B220^+CD43^+BP1^-CD24^{int}$), pro-B cells (fraction B/C; $B220^+CD43^+BP1^-CD24^+$), large pre-B cells (fraction C’; $B220^+CD43^+BP1^+CD24^+$), small pre-B cells (fraction D; $B220^+CD43^-IgM^-$), immature B cells (fraction E; $B220^+CD43^-IgM^+$), and recirculating mature B cells (fraction F; $B220^{hi}CD43^-IgM^+$). In the absence of CHD4, percentages of the earliest B cell progenitor populations (prepro-B and early pro-B) are increased, while later stages including pro-B through immature B cells and mature recirculating B cells are greatly decreased in mutant bone marrow (Fig. 2). Additionally, the lack of positive staining for cell surface markers $BP1^+$, $CD25^+$, and IgM^+ cells defines the developmental arrest as occurring before differentiation to pre-B cells (Fig. 2) (41). Interestingly, pro-B cells from *Chd4^{cKO/cKO}* mice exhibited increased surface c-Kit ($CD117$) expression (Fig. 2 C and D). In addition, spleens isolated from *Chd4^{cKO/cKO}* mice were approximately one half the size of wild-type (WT) control spleens (SI Appendix, Fig. S2A). Spleens of *Chd4^{cKO/cKO}* mice exhibited a drastic reduction of IgM^+ - and IgD^+ -expressing B cells (SI Appendix, Fig. S2B). These data suggest that CHD4




Fig. 1. CHD4 depletion results in a total decrease of bone marrow and spleen cellularity. (A) Total cell counts of bone marrow cells harvested from 4- to 6-wk-old *Cd79a^{fl/fl}Cd79a-Cre^{Tg/+}* (*cKO*; $n = 21$) mice and WT ($n = 14$) mice. Each dot represents an individual mouse. (B) Total cell counts of spleenocytes harvested from 4- to 6-wk-old *Chd4^{fl/fl}Cd79a-Cre^{Tg/+}* ($n = 47$) and WT ($n = 61$) mice. Each dot represents an individual mouse. (C) Flow cytometry and (D) total numbers of $B220^+CD19^+$ cells isolated from bone marrow of *Chd4^{fl/fl}Cd79a-Cre^{Tg/+}* ($n = 13$) and WT ($n = 10$) mice. Each dot represents an individual mouse. Asterisks indicate statistical significance compared with WT littermate controls as unpaired, two-tailed Student’s *t* test without Welch’s correction. * $P < 0.05$, **** $P < 0.0001$. Graphs represent arithmetic mean with \pm SEM. All data are representative of at least three independent experiments.

deficiency impairs B cell development and differentiation in the bone marrow, which effectively prevents the establishment of mIg^+ B cell populations in the periphery.

CHD4-Deficient Pro-B Cells Have Impaired Responses to IL-7 Signaling.

Our flow cytometry studies indicated that CHD4 deficiency results in the arrest of bone marrow B cells at an early pro-B-like stage of development. Interleukin-7 receptor (IL-7R) signaling is essential for early B cell differentiation, survival, and proliferation (42, 43). Therefore, we hypothesized that the developmental arrest due to the loss of CHD4 is due, in part, to the inability of B cell progenitors to proliferate in response to IL-7. To test this hypothesis, IL-7-dependent proliferation and cell survival were assayed. Purified pro-B cells from WT and *Chd4^{cKO/cKO}* mice were stimulated with IL-7 and proliferation was measured by counting live cells over time (Fig. 3A). CHD4-deficient pro-B cells did not increase in number in the presence of IL-7, unlike WT pro-B cells, which actively proliferated.

To determine whether the lack of proliferation was due to decreased IL-7R signaling, we measured levels of surface CD127 (IL-7R α) on $B220^+CD43^+$ bone marrow cells from *Chd4^{cKO/cKO}* mice and WT littermate controls (Fig. 3 B and C). The frequencies of $CD127^+$ cells, as well as the level of CD127 expression (measured as mean fluorescence intensity, or MFI) were unaltered by CHD4 deficiency. However, we noted that downstream IL-7R signaling is reduced in CHD4-deficient pro-B




Fig. 2. B cell development is arrested at an early pro-B-like stage of development in the absence of CHD4. Quantitation of B cell subsets in bone marrow. (A) Flow cytometry and (B) frequencies and numbers of various B cell populations (Hardy fractions) from bone marrow of 4- to 6-wk-old *Chd4^{fl/fl}Cd79a-Cre^{Tg/+}* (*cKO*; $n = 29$) and WT ($n = 24$). (C) Flow cytometry and (D) frequencies (*cKO*, $n = 9$; WT, $n = 10$) and numbers (*cKO*, $n = 4$; WT, $n = 4$) of CD19⁺ and CD19⁺ c-Kit⁺ cells from bone marrow of 4- to 6-wk-old *Chd4^{fl/fl}Cd79a-Cre^{Tg/+}* and WT mice. Asterisks indicate statistical significance compared with WT littermate controls using two-way ANOVA with Sidak's multiple comparisons test. * $P < 0.05$, ** $P < 0.005$, *** $P < 0.0005$, **** $P < 0.0001$. Graphs represent arithmetic mean with \pm SEM. All data are representative of at least three independent experiments.

cells. We examined intracellular Signal Transducer and Activator of Transcription 5A (STAT5A) phosphorylation after stimulation with IL-7 in vitro, because STAT5A is an essential downstream effector of IL-7R signaling in early B cell development and differentiation (44, 45). Intracellular flow cytometry detected decreased total phosphorylated STAT5A in CHD4-deficient pro-B cells (Fig. 3 D and E). These data suggest that IL-7R signaling is defective in CHD4-deficient pro-B cells.

CHD4 Is Required for Distal V_H to DJ_H Usage and *Igh* Locus Contraction. V(D)J recombination depends on the accessibility of recombination signal sequences (RSSs) to the recombinase machinery (46). It has been reported that IL-7R signaling plays a vital role in modulating the accessibility of chromatin during these events (47, 48). Therefore, we assessed the status of V(D)J recombination in cells lacking CHD4 and IL-7R signaling using genomic qPCR (Fig. 4A). We sorted c-Kit⁺ and c-Kit^{low} pro-B cells from *Chd4^{cKO/cKO}* and WT control mice and quantified frequencies of DJ_H rearrangements with distal V_H558 family versus proximal V_H7183 family gene segments to determine accessibility of these sites. Genomic qPCR detected similar utilization of distal V_H558 and proximal V_H7183 segments in rearranged alleles from CHD4-deficient c-Kit⁺ pro-B cells, CHD4-deficient c-Kit^{low} pro-B cells, and WT c-Kit⁺ pro-B cells. In contrast, utilization of distal V_H558 gene segments in c-Kit^{low} pro-B cells isolated from CHD4-deficient mice was decreased by fourfold. To further explore the mechanisms contributing to defective V(D)J recombination in CHD4-deficient mice, we purified pro-B cells from bone marrow of *Chd4^{cKO/cKO}* and WT control mice and stained cells to detect cytoplasmic μ -chains (Fig. 4B). CHD4-deficient B cells lacked cytoplasmic μ -chains, similar to B cells from *Rag1* knockout mice (Fig. 4C). Other genes associated with *Igh* recombination, including *Pax5-activated intergenic repeat 4* (*Pair4*), *Pair6*, and $\mu 0$, which produce noncoding germline transcripts, and $C\mu$ constant region mRNA (from DJ_H rearranged loci

(49–52), were detected at WT levels in CHD4-deficient pro-B cells (SI Appendix, Fig. S3A).

The decreased usage of distal V_H segments in CHD4-deficient pro-B cells could be due to an inability to generate long-range interactions between V_H and $D-J_H$ loci. Therefore, we assessed the topology of *Igh* loci in early pro-B cells using 3D fluorescence in situ hybridization (3D-FISH) with labeled BAC probes (Fig. 4D and E). The 3D-FISH detected greater distances between hybridized proximal (IgH404) and distal V_H (IgH189) probes (median distance 0.30 μ m) in CHD4-deficient versus WT pro-B cells (median distance 0.23 μ m) with high significance ($P < 0.0001$). Taken together, our results suggest that CHD4 has a role in locus contraction of *Igh* loci, but further details of this mechanism remain to be determined.

CHD4-Deficient Pro-B Cells Have Higher Frequencies of DNA Damage. Impairment of locus contraction and the inability to efficiently complete *Igh* rearrangements in CHD4-deficient pro-B cells could involve dysregulation of DNA damage response (DDR) pathways. V(D)J recombination is intimately coupled with DNA double-stranded break (DSB) repair. Cleavage of RSSs by Recombination Activating Gene (RAG-1 and RAG-2)-mediated DSBs activate Ataxia-Telangiectasia Mutated (ATM) kinase, which in turn initiates DDR (reviewed in ref. 53). CHD4 has been extensively studied as a key component of DDR pathways, where it is phosphorylated by ATM and recruited during the repair of DSBs (33). To assess DNA damage due to the loss of CHD4 directly, we measured amounts of intracellular γ -H2AX (phosphorylated on Ser139) in pro-B cells using flow cytometry. Pro-B cells lacking CHD4 exhibited a significant increase in the intracellular staining of γ -H2AX (Fig. 4F and G). The results indicate that CHD4 deficiency increases the accumulation of DNA damage due to impaired DDR. This deficiency may be due to RAG DSBs failing to initiate the transcriptional program necessary to carry out these functions due to the loss of CHD4.




Fig. 3. CHD4 is required for proliferation of pro-B cells downstream of IL-7R signaling. (A) Pro-B cells (B220⁺CD43⁺CD24⁺BP1⁺IgM⁻) were sorted from *Chd4*^{fl/fl}*Cd79a-Cre*^{Tg/+} mice (*cKO*; *n* = 3) and WT littermate controls (*n* = 3) for culture in IL-7 (10 ng/mL). Cell counts were taken daily for 7 d, represented as the number of cells over the initial cell count. Asterisks indicate statistical significance compared with WT littermate controls using two-way ANOVA with Sidak's multiple comparisons test. ***P* < 0.005, *****P* < 0.0001. Graphs represent arithmetic mean with \pm SEM. All data are representative of at least three independent experiments. (B) Representative flow cytometry of CD127 (IL-7R α) expression on B220⁺CD43⁺ cells isolated from *Chd4*^{fl/fl}*Cd79a-Cre*^{Tg/+} and WT littermate controls. (C) Total numbers of B220⁺CD43⁺CD127⁺ cells from the bone marrow of *Chd4*^{fl/fl}*Cd79a-Cre*^{Tg/+} and WT littermate controls. (D) Representative flow cytometry of intracellular phosphor-STAT5a in c-Kit⁺ pro-B cells (Lin⁻CD19⁺c-Kit⁺CD25⁻IgM⁻IgD⁻) isolated from *Chd4*^{fl/fl}*Cd79a-Cre*^{Tg/+} and WT littermate controls. (E) Detection of pSTAT5A in CD19⁺c-Kit⁺ pro-B cells isolated from *Chd4*^{fl/fl}*Cd79a-Cre*^{Tg/+} (*n* = 3) and WT (*n* = 3) mice. The lineage (Lin) stain included: CD3e, CD11b, CD11c, Gr-1, NK1.1, Ly6c, CD317, and Ter119. Asterisks indicate statistical significance compared with WT littermate controls as unpaired, two-tailed Student's *t* test without Welch's correction. **P* < 0.05, ***P* < 0.005, *****P* < 0.0001, NS, not significant. Graphs represent arithmetic mean \pm SD. All data are representative of at least three independent experiments.

Alternatively, we cannot rule out the initiation of damage by Cre-mediated DSBs.

CHD4 Is Essential for Repression of Inappropriate Transcription in Early Pro-B Cells. Correct transcriptome expression is essential for normal B cell developmental progression. Because CHD4-NuRD is a known corepressor of transcription, we sought to determine whether CHD4-deficient early pro-B cells exhibit altered transcriptomes relative to their WT counterparts. We employed RNA sequencing (RNA-seq) to interrogate genome-wide changes in transcription. Purity of sorted populations was assessed and principal component (PC) analysis of RNA-seq was performed to determine relationships between biological replicates (SI Appendix, Fig. S4 A and B). A total of 3,318 unique genes were differentially regulated between CHD4-deficient and

WT pro-B cells (≥ 1.5 fold, $P_{\text{adj}} < 0.05$) (Dataset S1). In the absence of CHD4, 1,241 genes were significantly down-regulated and 2,077 genes were significantly up-regulated (Fig. 5A).

Phenotypic analysis demonstrated the loss of lineage progression in *Chd4*^{cKO/cKO} B cells. Therefore, we assessed whether key genes necessary for early B cell development were differentially expressed in *Chd4*^{cKO/cKO} pro-B cells (Fig. 5B). Transcripts associated with B cell progenitor specification and commitment, including *Ebf1*, *Pax5*, and *Cd19*, as well as the expression of other transcription factors, including *Ikzf1*, *Ets1*, *Spi1*, and *Spib*, were unchanged in CHD4-deficient pro-B cells. Loss of CHD4 resulted in increased *Kit* transcripts (1.7-fold), which are normally down-regulated before differentiation to canonical pro-B (fraction B) cells. Loss of CHD4 expression in pro-B cells did not affect the expression of *Flt3* together with components of the pre-BCR, including *Cd79b*, *Igll1*, and *Vpreb1*. We detected reduced expression of *Cd79a* (reduced by 30%), which is not unexpected in the presence of the *Cd79a-Cre* allele. It is notable that *Foxo1* and *Rag1*, which are necessary for V(D)J recombination, are up-regulated 1.5-fold in CHD4-deficient pro-B cells. Up-regulation of *Rag1* is consistent with findings that IL-7R signaling and *Rag1* expression are inversely correlated (48, 54).

Genes that constitute normal transcriptional signatures of subsequent progenitor stages, i.e., late pro-B cells and pre-B cells, including *Il2ra* and *Enpep* (encoding CD25 and BP-1), are activated first at low levels in WT pro-B cells. Transcripts of these late pro-B and pre-B cell genes were significantly reduced in CHD4-deficient pro-B cells, indicating that these cells fail to activate genes associated with the transition to subsequent stages of differentiation. In conjunction with our phenotypic analysis, these data further support requirements for CHD4 in the transition from early pro-B cells to late pro-B/pre-B cells.

We next identified affected pathways in CHD4-deficient pro-B cells using ingenuity pathway analysis (IPA) (Fig. 5C). CHD4 deficiency largely resulted in the enrichment of genes representing pathways in that feature prominently in cell populations other than B cells, including T cells, neuronal cells, heart and skeletal muscle cells, and other nonhematopoietic cells. Specifically, pathways activated in CHD4-deficient pro-B cells include *NFAT signaling in cardiac hypertrophy*, *PKC θ signaling in T lymphocytes*, *Thrombin Signaling*, and *CREB signaling in neurons*. In fact, many genes that are not normally expressed in B cells, but are expressed in other cell lineages, are significantly up-regulated in CHD4-deficient pro-B cells (Fig. 5D and E). The most highly up-regulated genes in CHD4-deficient pro-B cells include *Igll5*, encoding a neural cell adhesion protein (55), *Chromogranin A (Chga)*, a glycoprotein expressed in the pancreas and neuronal cells, and *FYVE, RhoGEF, and PH Domain containing 5 (Fgd5)*, which is a highly specific diagnostic marker of hematopoietic stem cells (56). Significant promiscuous expression of genes of other lineages, including endocrine genes and the lung and neuronal genes was noted. These genes include *glucagon receptor/Gcgr*, which is normally expressed in the liver, *Huntingtin-associated protein 1/Hap1*, expressed in the CNS, and multiple lung-expressed genes including *laminin $\alpha 5$ (Lama5)*. Expression of these genes in CHD4-deficient pro-B cells indicates that CHD4 contributes to B cell lineage specification by repressing transcription of nonlineage gene programs.

To identify potential upstream regulators of the gene expression signature, we utilized IPA upstream regulator analysis (Fig. 5F). Our results indicate that many transcriptional regulators, including TGFB1, TP53, STAT4, SOX4, and EP300, are predicted to activate gene transcription in CHD4-deficient pro-B cells. Notably, regulators important for the regulation or transcriptional silencing, including TRIM24, CBX5, and CHD4 itself, are predicted to be inhibited.

CHD4 Modulates Chromatin Accessibility in Early Pro-B Cells. Given that CHD4 is a repressor of transcription and known to limit




Fig. 4. Loss of CHD4 results in reduced V_H to DJ_H rearrangements and increased DNA damage in pro-B cells. (A) qPCR analysis of rearranged proximal (V_H7183) and distal (V_HJ558) gene segments from genomic DNA isolated from sorted c-Kit⁺ pro-B cells ($\text{Lin}^- \text{CD}19^+ \text{c-Kit}^+ \text{CD}25^- \text{IgM}^- \text{IgD}^-$) and c-Kit^{low} pro-B cells ($\text{Lin}^- \text{CD}19^+ \text{c-Kit}^{\text{low}} \text{CD}25^- \text{IgM}^- \text{IgD}^-$) from bone marrow of 4- to 6-wk-old $\text{Chd}4^{\text{fl/fl}} \text{Cd}79\text{a-Cre}^{\text{Tg}/+}$ mice ($n = 3$) and WT littermate controls ($n = 3$). (B) Flow cytometry of cytoplasmic Ig μ -expression in sorted $\text{B}220^+ \text{CD}43^+ \text{sIgM}^-$ B cells isolated from bone marrow from 4- to 6-wk-old $\text{Chd}4^{\text{fl/fl}} \text{Cd}79\text{a-Cre}^{\text{Tg}/+}$ ($n = 2$) and WT ($n = 2$) mice. (C) Flow cytometry of cytoplasmic Ig μ -expression in sorted $\text{B}220^+ \text{CD}43^+ \text{sIgM}^-$ B cells isolated from bone marrow from 4- to 6-wk-old $\text{Chd}4^{\text{fl/fl}} \text{Cd}79\text{a-Cre}^{\text{Tg}/+}$ ($n = 2$) and a $\text{Rag}1$ knockout mouse ($n = 1$). Data are derived from one experiment. (D) The 3D-FISH confocal images of hybridized probes in $\text{CD}19^+ \text{c-Kit}^+$ pro-B cell (as described above) nuclei isolated from bone marrow of $\text{Chd}4^{\text{fl/fl}} \text{Cd}79\text{a-Cre}^{\text{Tg}/+}$ and WT mice. The IgH404 proximal probe (RP23-404D8) was labeled with Alexa Fluor 488 (AF488); the IgH189 distal probe (RP23-189H12) was labeled with AF568; major satellite repeats (γ -sat) were conjugated to AF647; and nuclei were counterstained with DAPI. (E) Distributions of spatial distances (in micrometers) separating BAC probes, located at each end of the *Igh* locus (IgH404 vs. IgH189) in pro-B cells isolated from bone marrow of $\text{Chd}4^{\text{fl/fl}} \text{Cd}79\text{a-Cre}^{\text{Tg}/+}$ ($n = 92$ cells) and WT ($n = 69$ cells). Each dot represents an individual allele. (F) Representative flow cytometry and (G) MFI of c-Kit⁺ pro-B cells stained for intracellular γ -H2AX from bone marrow of $\text{Chd}4^{\text{fl/fl}} \text{Cd}79\text{a-Cre}^{\text{Tg}/+}$ ($n = 4$) and WT ($n = 3$) mice. The asterisks indicate statistical significance compared with the WT littermate controls as unpaired, two-tailed Student's *t* test with equal SD, Mann-Whitney rank test or two-way ANOVA with Sidak's multiple comparisons test. *** $P < 0.0005$, **** $P < 0.0001$. All data are representative of at least three independent experiments.

chromatin accessibility of individual genes (36), we employed the assay for transposase-accessible chromatin-coupled with next generation sequencing (ATAC-seq) to determine whether chromatin landscape alterations occur in parallel with the significantly changed transcriptional pattern observed in CHD4-deficient pro-B cells. We compared ATAC-seq peaks between CHD4-deficient and WT pro-B cells. Consistent with CHD4's role as a chromatin remodeler, we observed ~35,000 more accessible peaks in CHD4-deficient pro-B cells (Fig. 6A). CHD4-deficient pro-B cells also contained ~20,000 fewer accessible peaks vs. WT cells. The majority of these differential ATAC-seq peaks localize to intergenic or intronic regions, while ~4% reside within promoter/TSS chromatin regions based on HOMER annotation (Fig. 6B). To interrogate the potential functional links between the altered chromatin landscape and transcriptional programming governing B cell development, we integrated the differential RNA- and ATAC-seq datasets comparing CHD4-deficient vs. WT pro-B cells (Fig. 6C). The majority (2,393 genes or ~72%) of differentially expressed genes determined via RNA-seq (1.5-fold cutoff), also exhibited altered chromatin accessibility in CHD4-deficient pro-B cells. Not surprisingly, complex patterns of increased and decreased accessibility mark genes with both increased and decreased gene expression in CHD4-deficient pro-B cells. Specifically, of the 2,077 genes with increased expression in CHD4-deficient pro-B cells, ~70%, or 1,445 genes, exhibited increased chromatin accessibility (Fig. 6C). In contrast, of the 1,241 genes with decreased expression in CHD4-deficient pro-B

cells, less than half, or 593 genes, exhibited decreased accessibility. In addition, evidence linking local repressor activity of CHD4 to increased accessibility and gene expression in CHD4-deficient pro-B cells is further supported by comparing our datasets with previously reported ChIP-seq analysis of CHD4 DNA binding (7). Of the 34,219 CHD4 binding signals detected in both replicates of RAG-deficient pro-B cells, 7,198 signals (21%) were detected within 10 kb of TSS in genes that change expression in our CHD4-deficient pro-B cells (estimated with 1.5-fold cutoff of significance). Together, these data largely support a role for CHD4 as a corepressor that controls chromatin accessibility in the early B cell developmental program.

Given the ability of CHD4 to regulate transcriptional machinery at promoter regions, we assessed the chromatin distribution for the least confounded integration of ATAC-seq data with RNA-seq data. Specifically, we analyzed the 800 peaks with only increased accessibility and increased gene expression and the 195 peaks with only decreased accessibility and decreased gene expression (Fig. 6D and E). Compared with the total differential ATAC-seq peak distribution comparing CHD4-deficient vs. WT pro-B cells (Fig. 6B), the 800 ATAC-seq peaks linked to increased gene expression displayed an almost twofold increase (7% vs. 4%) in promoter/TSS distribution and a specific loss of distribution to intergenic regions (33% vs. 45%) (Fig. 6D). Similarly, the 195 ATAC-seq peaks linked to decreased gene expression displayed a greater than twofold increase (10% vs. 4%) in promoter/TSS localization (29% vs. 45%) (Fig. 6E). The enhanced promoter/TSS localization




Fig. 5. CHD4 is required for transcriptional repression of non-B lineage genes. (A) Volcano plot of expression in transcripts per million (TPM) of genes in *Chd4^{fl/fl};Cd79a-Cre^{Tg/+} c-Kit⁺* pro-B cells. Genes significantly increased (red) and decreased (blue) greater than 1.5-fold ($P_{adj} \leq 0.05$) are highlighted. (B) Heatmap depicting TPM of select B-lineage genes. (C) IPA enrichment for the top 10 most significantly enriched canonical pathways. (D) Heatmap of TPM values for non-B lineage genes. (E) Validation (qRT-PCR) of select up-regulated non-B lineage genes in CHD4-deficient and WT pro-B cells. Statistical significance of RT-PCR data was validated using the Mann-Whitney rank test: * $P < 0.05$, *** $P < 0.0005$. (F) IPA upstream regulators predicted as activated (red) and inhibited (blue).




Fig. 6. CHD4 modulates chromatin accessibility in early pro-B cells. (A) Comparison of filtered, statistically called ATAC-seq peaks between CHD4-deficient and WT pro-B cells. (B) Analysis of HOMER annotated regions within differential peaks called between CHD4-deficient and WT pro-B cells. (C) Integration and comparison of differential RNA-seq and ATAC-seq datasets between CHD4-deficient and WT pro-B cells. The 800 gene set (up-regulated with only open peaks) and 195 gene set (down-regulated with only closed peaks) are circled red and black, respectively. (D) Assessment of chromatin distribution within 800 gene set (RNA-seq/ATAC-seq integration) between CHD4-deficient and WT pro-B cells. (E) Assessment of chromatin distribution within 195 gene set (RNA-seq/ATAC-seq integration) between CHD4-deficient and WT pro-B cells. (F) Heatmap of GO pathway analysis for the total set of RNA-seq differentially expressed genes compared with the number of shared genes between each Venn subgroup and the total genes within each GO pathway. (G) Visualization of *Fgd5* gene landscape (integration of RNA-seq and ATAC-seq datasets) between CHD4-deficient and WT pro-B cells. (H) Visualization of *Fcrla* gene landscape (integration of RNA-seq and ATAC-seq datasets) between CHD4-deficient and WT pro-B cells.

and decrease in intergenic regions suggests that CHD4 regulates transcription in pro-B cells via direct regulation of chromatin accessibility. To further investigate this hypothesis, we examined the DNA binding motifs associated with promoter-localized ATAC-seq peaks using HOMER (Dataset S2). Analysis of the promoter annotated ATAC-seq peaks within the 800 gene set Venn subgroup revealed enrichments in E26 Transforming Sequence (ETS), zinc finger (Zf), and Myocyte Enhancer Factor 2 (MEF2) transcription factor binding sites. In contrast, analysis of the promoter annotated ATAC-seq peaks within the 195 subgroup revealed enrichment in Pit1-Oct1-Unc86 (POU) domain protein binding sites.

To further examine the biological significance of the CHD4 chromatin-regulated program in pro-B cells, we employed gene ontology (GO) analysis to identify the contributions of specific chromatin-regulated Venn gene sets (Fig. 6C) to transcriptionally driven biological pathways. GO pathway analysis was performed for the total set of 3,318 RNA-seq differentially expressed genes. The contribution of each Venn gene set to the expression-based biological pathways was determined by comparing the number of shared genes between each Venn subgroup and the total genes within each GO pathway. We then generated a heatmap based on the ratio of the gene number comparison for each Venn subgroup (Fig. 6F). This analysis reveals that the biological programs identified via the RNA-seq analysis of the CHD4-deficient pro-B cells is being driven by the 800 and 645 gene sets, which link increased accessibility with gene transcription. The shared GO terms for those two gene subsets distribute among immune and neural development, cell morphology, and cell signaling pathways (Dataset S3). These data support the role of CHD4 in enforcing transcription of a biological program, while repressing other programs in B cells.

Finally, to visualize the coordinated chromatin and transcriptional changes in CHD4-deficient vs. WT pro-B cells, we integrated ATAC- and RNA-seq data for specific genes using the integrative genomics viewer (IGV) (Fig. 6G and H). We compared visualization of the inappropriately activated (increased 63.7-fold) *Fgd5* locus (Fig. 6G), with the down-regulated (decreased by 67%) *Fcrla* locus (Fig. 6H). With loss of CHD4, the *Fgd5* locus is characterized by increased chromatin accessibility and gene expression in mutant pro-B cells, while the *Fcrla* locus features decreased chromatin accessibility. These data are consistent with the hypothesis that CHD4 represses prior hematopoietic programs (including *Fgd5*) as B cell differentiation proceeds. Conversely, *Fcrla* is expressed in more mature B cells following further differentiation. Decreased *Fcrla* expression may be due to the lack of progression accompanying developmental arrest in CHD4-deficient pro-B cells.

Discussion

The network of transcription factors that orchestrate B cell development has been defined extensively. However, less understood are the functions of epigenetic regulators including chromatin remodeling complexes, which likely play pivotal roles in specifying patterns of gene expression in developing lymphocytes. A key group of these complexes is encompassed as NuRD, which while largely implicated as corepressors may regulate an array of transcriptional outcomes (27). In this study, we investigated functions of a catalytic ATPase/helicase subunit of NuRD complexes, CHD4. Mice lacking CHD4 in the early B cell compartment exhibit a developmental blockade at an early pro-B-like (c-Kit⁺CD19⁺) stage of development. CHD4-deficient pro-B cells do not proliferate in response to IL-7, are defective in V(D)J recombination, and accumulate DNA damage. Strikingly, pro-B cells lacking CHD4 have lost the ability to progress to later B cell stages, together with inappropriate expression of hundreds of non-B lineage genes. These defects result in the failure of CHD4-deficient early pro-B cells to differentiate into antibody-producing B cells. Developmental arrest occurs despite

relatively normal expression of transcription factors that are essential for B cell lineage specification and commitment, including EBF1 and Pax5.

Loss of CHD4 in pro-B cells changes the relative expression of more than 3,000 genes. Thus, CHD4 and CHD4-NuRD complexes are widely employed to establish appropriate transcriptional patterns in B cells. Genes that are dependent on CHD4 for normal expression participate in key pathways necessary for B cell development, including IL-7 signaling and V(D)J recombination. The extensive list of affected genes related to these pathways makes it difficult to define a single mechanism that drives developmental arrest. This process involves both direct and indirect mechanisms that influence chromatin dynamics and transcription. Given this multifactorial regulation of lineage specification, further studies will be required to delineate the contributions of specific factors, such as CHD4, for the regulation of transcriptional and epigenetic programs defining B cell differentiation. However, a common underlying theme in each of these pathways is the impact of defective IL-7R signaling, which blocks proliferation. These effects may be exacerbated by the cells' inability to undergo DNA damage repair and complete V(D)J recombination.

The most distinguishing characteristic of B cells is the productive rearrangement of Ig genes, which generates a diverse repertoire of antigen-specific receptors. Our data indicate that V(D)J recombination is impaired in CHD4-deficient pro-B cells. This conclusion is evidenced by defects in distal V_H rearrangements which may be due, in part, to defective *Igh* locus contraction. Consistent with other studies, our RNA-seq data indicate that a number of components necessary for V(D)J recombination are expressed, and even up-regulated in CHD4-deficient pro-B cells, including *Rag1*, *Foxo1*, and *Foxo3a* transcripts, while IL-7R signaling is attenuated. In normal pro-B cells, transcription of these elements reflects increased chromatin accessibility at *Igh* loci (50). As evidenced by our 3D-FISH studies, the inefficient completion of distal V_H gene rearrangements in CHD4-deficient pro-B cells may be due to an inability to establish long-range genomic interactions necessary for recombination with distant $D-J_H$ loci. Transcripts encoding multiple factors implicated in locus contraction, including *Pax5*, *Ezh2*, *Brg1*, *Ikzf1*, *Tfe3*, and *Yy1* (57–62), were unchanged in pro-B cells isolated from CHD4-deficient vs. WT pro-B cells, suggesting that CHD4 may function downstream of proteins encoded by these genes. Rearrangements of distal V_H 558 segments may also be reduced in CHD4-deficient pro-B cells due to defects in IL-7R signaling, which recruits STAT5 to distal V_H segments and increases accessibility of local chromatin (63). However, it is difficult to distinguish whether reduced *Igh* locus contraction is due to defects in intrinsic mechanisms of locus contraction, or whether developmental arrest occurs before the initiation of distal V_H rearrangements in the mutant mice.

CHD4 has been linked with the fidelity of lineage-appropriate transcriptional programs (27, 64). Here, we determined that expression of CHD4 is important for establishing the pro-B cell program: CHD4-deficient pro-B cells promiscuously express transcripts of genes that are normally restricted to other lineages. Interestingly, NuRD complexes are important regulators of pluripotency and self-renewal in embryonic stem cells (reviewed in ref. 65). Two recent reports that examined CHD4-deficient embryos described changes in lineage commitment, with promiscuous expression of lineage marker genes that are related to a wide range of fate decisions (66, 67). Another study of requirements for cardiac striated muscle development reported that loss of CHD4 resulted in inappropriate expression of skeletal muscle gene expression; conversely, loss of CHD4 in skeletal muscle led to expression of key striated muscle genes (68). Thus, our data complement other studies demonstrating that CHD4 acts as a

“gatekeeper” of lineage specification by controlling stem cell- and differentiation-associated genes in multiple tissues.

The question arises: Why are genes selectively up-regulated in the absence of CHD4? Certainly, the loss of CHD4 depletes pro-B cells of CHD4-NuRD, which can repress chromatin accessibility at genes that are normally silenced in these cells. We hypothesize that the loss of CHD4-dependent repression of genes that characterize other tissues, including the CNS, pancreas, and lung, makes these genes susceptible to activation by factors that are shared in common between pro-B and multiple cell types, but are normally insufficient to activate transcription in the presence of CHD4. Notably, HOMER analysis detected binding sites for ETS family proteins and other transcription factors frequently in new ATAC-seq peaks of 800 up-regulated genes (Fig. 6C and Dataset S2). These factors may activate transcription in synergy with other CRCs that colocalize at sites with CHD4-NuRD (e.g., Brg1; ref. 64). Alternatively, the absence of CHD4 may derepress expression of transcription factors necessary to “pioneer” non-B cell transcriptional programs. In non-B cell lineages, these drivers of other programs may overcome barriers imposed by CHD4-NuRD (or related CRCs) for transcriptional activation of lineage-specific genes. Conversely, the loss of ATAC-seq peaks and transcript expression of 195 genes correlated with binding sites for POU domain transcription factors within those peaks. We hypothesize that POU transcription factors are necessary for activation of these genes during developmental progression. Interestingly, half of the genes that fail to be activated in CHD4-deficient pro-B cells maintained their patterns of accessibility, as detected by ATAC-seq. This set of genes may be poised for transcriptional activation but are unable to be expressed due to the absence of a factor(s) necessary for developmental progression. Alternatively, small changes in the positioning of nucleosomes may block the binding of an essential activator(s) in the absence of CHD4 (27).

Loss of CHD4 function contributes to human diseases, but the full scope of its involvement is unknown. The partial or complete loss of CHD4 due to mutations is a driver of cancer (69, 70). Loss of CHD4 leads to unrepaired DNA DSBs (and microsatellite instability) that lead to deletions and chromosomal translocations (71). Interestingly, leukemogenesis is induced, in part, by redistribution of CHD4-NuRD complexes to new gene targets in lymphocytes in the absence of IKZF1 (Ikaros) (26). Thus, loss of function or inappropriate recruitment of CHD4-NuRD complexes each promote tumorigenesis. Additionally, the control of

lineage specification by CHD4 in B cells suggests potential deleterious effects of its loss of function. If mature B cells with mutations in *Chd4* genes (resulting in reduced CHD4 expression, but not cell death) persist at peripheral sites, inappropriate expression of non-B cell proteins in professional antigen-presenting cells may result in the display of novel antigenic determinants (i.e., neoantigens) that initiate autoimmune responses. Importantly, a series of de novo missense mutations in *CHD4* genes have been detected in humans, resulting in intellectual disabilities and distinctive dysmorphisms (72).

Together, our studies demonstrated how CHD4, a key component of NuRD CRC, is required for the early development and lineage progression of B cells. In the future, additional studies will be necessary to integrate functions of CHD4 within a transcriptional network of regulators of B cell development and function.

Materials and Methods

Materials, including mouse models used and generated by this work, are available in *SI Appendix*. Mice were bred and housed in the Biological Resources Center at National Jewish Health. All experiments were performed under a protocol (AS2558-04-20) approved by the Institutional Animal Care and Use Committee at National Jewish Health. Reagents and methods used for cell preparation, flow cytometry, and cell culture; methods for analysis of STAT5 phosphorylation, qPCR analysis of IgH V_H usage, 3D-FISH, confocal microscopy, and analysis of DNA damage are described in *SI Appendix*. Preparation of libraries, RNA-seq, and ATAC-seq were performed at the Center for Genes and Environment at National Jewish Health and are detailed in *SI Appendix*. Bioinformatic analysis of RNA-seq and ATAC-seq, including comparison with CHD4 ChIP-seq, and other statistical analysis, are described in *SI Appendix*.

ACKNOWLEDGMENTS. We thank J. Svaren and J. Cambier for the gifts of the *Chd4* floxed and *Cd79a-Cre^{Tg/+}* mice; H. Huang and L. Wysocki for the constitutively active Stat5a and Igu plasmids, respectively; R. Torres, C. Porter, A. Bhandoola, and E. Oltz for their insights; H. Lei and F. Han for excellent technical assistance; S. Welsh, K. Lukin, and J. Ramirez for helpful scientific discussions; Mark Dell’Ariaga for critically reading the paper and helping with illustrations; and J. Loomis (National Jewish Flow Cytometry core) for excellent technical assistance. J.R.H. acknowledges NIH Awards R01AI081878, R01AI098417, R21AI115696, and a generous grant from the Wendy Siegel Fund for Leukemia and Cancer Research. T.A. was supported by the Victor W. Bolie and Earleen D. Bolie Graduate Scholarship Fund. C.D. was supported by a Cancer Research Institute Predoctoral Emphasis Pathway in Tumor Immunology Fellowship. A.B. was supported by the NIH, under Award F32 GM106631. C.J.F. was supported by the NIH Institutional National Service Award 2T32AI07449. A.J.F. was funded by NIH Grants R01AI21286, R21AI107343, and R03AI1154861. C.M. was funded by NIH Grant R01AI109599. B.P.O. acknowledges support by NIH Grant R01HL127461.

- Abdelrasoul H, Werner M, Setz CS, Okkenhaug K, Jumaa H (2018) PI3K induces B-cell development and regulates B cell identity. *Sci Rep* 8:1327.
- Miyai T, et al. (2018) Three-step transcriptional priming that drives the commitment of multipotent progenitors toward B cells. *Genes Dev* 32:112–126.
- Revilla-I-Domingo R, et al. (2012) The B-cell identity factor Pax5 regulates distinct transcriptional programmes in early and late B lymphopoiesis. *EMBO J* 31:3130–3146.
- Li R, et al. (2018) Dynamic EBF1 occupancy directs sequential epigenetic and transcriptional events in B-cell programming. *Genes Dev* 32:96–111.
- Maier H, et al. (2004) Early B cell factor cooperates with Runx1 and mediates epigenetic changes associated with mb-1 transcription. *Nat Immunol* 5:1069–1077.
- McManus S, et al. (2011) The transcription factor Pax5 regulates its target genes by recruiting chromatin-modifying proteins in committed B cells. *EMBO J* 30:2388–2404.
- Schwickert TA, et al. (2014) Stage-specific control of early B cell development by the transcription factor Ikaros. *Nat Immunol* 15:283–293.
- Tong JK, Hassig CA, Schmitzler GR, Kingston RE, Schreiber SL (1998) Chromatin deacetylation by an ATP-dependent nucleosome remodeling complex. *Nature* 395:917–921.
- Xue Y, et al. (1998) NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. *Mol Cell* 2:851–861.
- Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D (1998) The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. *Cell* 95:279–289.
- Dege C, Hagman J (2014) Mi-2/NuRD chromatin remodeling complexes regulate B and T-lymphocyte development and function. *Immunol Rev* 261:126–140.
- Gatchalian J, et al. (2017) Accessibility of the histone H3 tail in the nucleosome for binding of paired readers. *Nat Commun* 8:1489.
- Musselman CA, et al. (2009) Binding of the CHD4 PHD2 finger to histone H3 is modulated by covalent modifications. *Biochem J* 423:179–187.
- Musselman CA, et al. (2012) Bivalent recognition of nucleosomes by the tandem PHD fingers of the CHD4 ATPase is required for CHD4-mediated repression. *Proc Natl Acad Sci USA* 109:787–792.
- Tencer AH, et al. (2017) Covalent modifications of histone H3K9 promote binding of CHD3. *Cell Rep* 21:455–466.
- Ramirez J, Dege C, Kutateladze TG, Hagman J (2012) MBD2 and multiple domains of CHD4 are required for transcriptional repression by Mi-2/NuRD complexes. *Mol Cell Biol* 32:5078–5088.
- Low JK, et al. (2016) CHD4 is a peripheral component of the nucleosome remodeling and deacetylase complex. *J Biol Chem* 291:15853–15866.
- Nitarska J, et al. (2016) A functional switch of NuRD chromatin remodeling complex subunits regulates mouse cortical development. *Cell Rep* 17:1683–1698.
- Allen HF, Wade PA, Kutateladze TG (2013) The NuRD architecture. *Cell Mol Life Sci* 70:3513–3524.
- Fujita N, et al. (2004) MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. *Cell* 119:75–86.
- Jaye DL, et al. (2007) The BCL6-associated transcriptional co-repressor, MTA3, is selectively expressed by germinal centre B cells and lymphomas of putative germinal centre derivation. *J Pathol* 213:106–115.
- Arenzana TL, Schjerve H, Smale ST (2015) Regulation of gene expression dynamics during developmental transitions by the Ikaros transcription factor. *Genes Dev* 29:1801–1816.
- Bottardi S, et al. (2014) The IKAROS interaction with a complex including chromatin remodeling and transcription elongation activities is required for hematopoiesis. *PLoS Genet* 10:e1004827.
- Kim J, et al. (1999) Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. *Immunity* 10:345–355.
- Liang Z, et al. (2017) A high-resolution map of transcriptional repression. *eLife* 6:e22767.

26. Zhang J, et al. (2011) Harnessing of the nucleosome-remodeling-deacetylase complex controls lymphocyte development and prevents leukemogenesis. *Nat Immunol* 13:86–94.
27. Bornelov S, et al. (2018) The nucleosome remodeling and deacetylation complex modulates chromatin structure at sites of active transcription to fine-tune gene expression. *Mol Cell* 71:56–72.e4.
28. Yamada T, et al. (2014) Promoter decommissioning by the NuRD chromatin remodeling complex triggers synaptic connectivity in the mammalian brain. *Neuron* 83:122–134.
29. O'Shaughnessy A, Hendrich B (2013) CHD4 in the DNA-damage response and cell cycle progression: Not so NuRDy now. *Biochem Soc Trans* 41:777–782.
30. Polo SE, Kaidi A, Baskcomb L, Galanty Y, Jackson SP (2010) Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4. *EMBO J* 29:3130–3139.
31. Smith R, Sellou H, Chapuis C, Huet S, Timinszky G (2018) CHD3 and CHD4 recruitment and chromatin remodeling activity at DNA breaks is promoted by early poly(ADP-ribose)-dependent chromatin relaxation. *Nucleic Acids Res* 46:6087–6098.
32. Larsen DH, et al. (2010) The chromatin-remodeling factor CHD4 coordinates signaling and repair after DNA damage. *J Cell Biol* 190:731–740.
33. Smeenk G, et al. (2010) The NuRD chromatin-remodeling complex regulates signaling and repair of DNA damage. *J Cell Biol* 190:741–749.
34. Curtis CD, Griffin CT (2012) The chromatin-remodeling enzymes BRG1 and CHD4 antagonistically regulate vascular Wnt signaling. *Mol Cell Biol* 32:1312–1320.
35. Urquhart AJ, Gatei M, Richard DJ, Khanna KK (2011) ATM mediated phosphorylation of CHD4 contributes to genome maintenance. *Genome Integr* 2:1.
36. Gao H, et al. (2009) Opposing effects of SWI/SNF and Mi-2/NuRD chromatin remodeling complexes on epigenetic reprogramming by EBF and Pax5. *Proc Natl Acad Sci USA* 106:11258–11263.
37. Williams CJ, et al. (2004) The chromatin remodeler Mi-2beta is required for CD4 expression and T cell development. *Immunity* 20:719–733.
38. Pelanda R, et al. (2002) Cre recombinase-controlled expression of the mb-1 allele. *Genesis* 32:154–157.
39. Hobeika E, et al. (2006) Testing gene function early in the B cell lineage in mb1-cre mice. *Proc Natl Acad Sci USA* 103:13789–13794.
40. Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K (1991) Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. *J Exp Med* 173:1213–1225.
41. Hardy RR, Kincaid PW, Dorshkind K (2007) The protean nature of cells in the B lymphocyte lineage. *Immunity* 26:703–714.
42. Peschon JJ, et al. (1994) Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. *J Exp Med* 180:1955–1960.
43. von Freeden-Jeffry U, et al. (1995) Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. *J Exp Med* 181:1519–1526.
44. Fistonich C, et al. (2018) Cell circuits between B cell progenitors and IL-7⁺ mesenchymal progenitor cells control B cell development. *J Exp Med* 215:2586–2599.
45. Goetz CA, Harmon IR, O'Neil JJ, Burchill MA, Farrar MA (2004) STAT5 activation underlies IL7 receptor-dependent B cell development. *J Immunol* 172:4770–4778.
46. Jung D, Alt FW (2004) Unraveling V(D)J recombination; insights into gene regulation. *Cell* 116:299–311.
47. Chowdhury D, Sen R (2003) Transient IL-7/IL-7R signaling provides a mechanism for feedback inhibition of immunoglobulin heavy chain gene rearrangements. *Immunity* 18:229–241.
48. Clark MR, Mandal M, Ochiai K, Singh H (2014) Orchestrating B cell lymphopoiesis through interplay of IL-7 receptor and pre-B cell receptor signalling. *Nat Rev Immunol* 14:69–80.
49. Ebert A, et al. (2011) The distal V(H) gene cluster of the Igh locus contains distinct regulatory elements with Pax5 transcription factor-dependent activity in pro-B cells. *Immunity* 34:175–187.
50. Verma-Gaur J, et al. (2012) Noncoding transcription within the Igh distal V(H) region at PAIR elements affects the 3D structure of the Igh locus in pro-B cells. *Proc Natl Acad Sci USA* 109:17004–17009.
51. Lennon GG, Pery RP (1985) C mu-containing transcripts initiate heterogeneously within the IgH enhancer region and contain a novel 5'-nontranslatable exon. *Nature* 318:475–478.
52. Thompson A, Timmers E, Schuurman RK, Hendriks RW (1995) Immunoglobulin heavy chain germ-line JH-C mu transcription in human precursor B lymphocytes initiates in a unique region upstream of DQ52. *Eur J Immunol* 25:257–261.
53. Bednarski JJ, Sleckman BP (2012) Lymphocyte development: Integration of DNA damage response signaling. *Adv Immunol* 116:175–204.
54. Johnson K, et al. (2012) IL-7 functionally segregates the pro-B cell stage by regulating transcription of recombination mediators across cell cycle. *J Immunol* 188:6084–6092.
55. Honorat JA, et al. (2017) IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients. *Neurol Neuroimmunol Neuroinflamm* 4:e385.
56. Gazit R, et al. (2014) Fgd5 identifies hematopoietic stem cells in the murine bone marrow. *J Exp Med* 211:1315–1331.
57. Bossen C, et al. (2015) The chromatin remodeler Brg1 activates enhancer repertoires to establish B cell identity and modulate cell growth. *Nat Immunol* 16:775–784.
58. Fuxa M, et al. (2004) Pax5 induces V-to-DJ rearrangements and locus contraction of the immunoglobulin heavy-chain gene. *Genes Dev* 18:411–422.
59. Liu H, et al. (2007) Yin Yang 1 is a critical regulator of B-cell development. *Genes Dev* 21:1179–1189.
60. Reynaud D, et al. (2008) Regulation of B cell fate commitment and immunoglobulin heavy-chain gene rearrangements by Ikaros. *Nat Immunol* 9:927–936.
61. Seet CS, Brumbaugh RL, Kee BL (2004) Early B cell factor promotes B lymphopoiesis with reduced interleukin 7 responsiveness in the absence of E2A. *J Exp Med* 199:1689–1700.
62. Su IH, et al. (2003) Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. *Nat Immunol* 4:124–131.
63. Bertolino E, et al. (2005) Regulation of interleukin 7-dependent immunoglobulin heavy-chain variable gene rearrangements by transcription factor STAT5. *Nat Immunol* 6:836–843.
64. Giles KA, et al. (2019) Integrated epigenomic analysis stratifies chromatin remodellers into distinct functional groups. *Epigenetics Chromatin* 12:12.
65. Hu G, Wade PA (2012) NuRD and pluripotency: A complex balancing act. *Cell Stem Cell* 10:497–503.
66. O'Shaughnessy-Kirwan A, Signolet J, Costello I, Gharbi S, Hendrich B (2015) Constraint of gene expression by the chromatin remodelling protein CHD4 facilitates lineage specification. *Development* 142:2586–2597.
67. Zhao H, et al. (2017) The chromatin remodeler Chd4 maintains embryonic stem cell identity by controlling pluripotency- and differentiation-associated genes. *J Biol Chem* 292:8507–8519.
68. Gómez-Del Arco P, et al. (2016) The chromatin remodeling complex chd4/NuRD controls striated muscle identity and metabolic homeostasis. *Cell Metab* 23:881–892.
69. Le Gallo M, et al.; NIH Intramural Sequencing Center (NISC) Comparative Sequencing Program (2012) Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. *Nat Genet* 44:1310–1315.
70. Kumar R, Li DQ, Müller S, Knapp S (2016) Epigenomic regulation of oncogenesis by chromatin remodeling. *Oncogene* 35:4423–4436.
71. Kim MS, Chung NG, Kang MR, Yoo NJ, Lee SH (2011) Genetic and expressional alterations of CHD genes in gastric and colorectal cancers. *Histopathology* 58:660–668.
72. Weiss K, et al.; DDD Study (2016) De novo mutations in CHD4, an ATP-dependent chromatin remodeler gene, cause an intellectual disability syndrome with distinctive dysmorphisms. *Am J Hum Genet* 99:934–941.